Bert Vogelstein - Cancer Science

Author Information

Bert Vogelstein is affiliated with The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, located in Baltimore, MD, USA. His work has significantly contributed to the field of cancer research.

Research Contributions

Bert Vogelstein has an extensive research portfolio, with a focus on cancer biology and treatment strategies. Some of his notable recent works include research on bispecific antibodies targeting the HIV-1 reservoir, performance evaluation of non-invasive urine assays for cancer detection, and the development of alpha-1 adrenergic receptor antagonists for preventing hyperinflammation and mortality from respiratory infections. He has also contributed to the understanding of mutational signatures in cancer, cancer immunotherapy, and the use of circulating tumor DNA analysis for informing adjuvant chemotherapy in colon cancer.

Aliases

Bert Vogelstein is also known by the aliases B Vogelstein and B. Vogelstein.

Publication and Citation Metrics

Citation Count	364,928
H-Index	269
Paper Count	891

Publications:

TCR-mimic bispecific antibodies to target the HIV-1 reservoir.

DOI: 10.1073/pnas.2123406119

Year: 2022

Correction to: Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

DOI: 10.1007/s00428-022-03292-w

Year: 2022

Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection

DOI: 10.7554/eLife.61700

Year: 2021

Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer

DOI: 10.7554/eLife.61082

Year: 2021

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19

DOI: 10.3389/fmed.2021.637647

Year: 2021

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs

DOI: 10.1101/2021.08.06.455336

Year: 2021

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis Plan

DOI: 10.1101/2021.09.02.21262816

Year: 2021

Targeting public neoantigens for cancer immunotherapy.

DOI: 10.1038/S43018-021-00210-Y

Year: 2021

An Isogenic Cell Line Panel for Sequence-Based Screening of Targeted Anti-Cancer Drugs

DOI: 10.2139/ssrn.3936778

Year: 2021

Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark

DOI: 10.1001/jamanetworkopen.2020.37053

Year: 2021

How Has Technology Influenced Cancer Research?

How Long Do Hospital Stays Usually Last?

How Does DNA Sequencing Guide Treatment Decisions?

What is the Prognostic Value of MYC in Cancer?

Who Participates in Phase I Trials?

What are the Common Mutations in the PI3K Pathway?

What is the Pneumococcal Conjugate Vaccine (PCV13)?

What is the Future of Enhanced Diagnostics in Cancer?

Why is DBMS Important in Cancer Research?

What are Coordination Issues in Cancer?

Partnered Content Networks

Relevant Topics